Among the BET inhibitors (BETi) that have moved to clinics, OTX015 (MK-8628) is the only one that has been shown to have a good brain-penetrating capability in preclinical models of glioblastoma and medulloblastoma [23,24] and has been used in Phase 1 studies against glioblastoma (https://clinicaltrials.gov, NCT 02296476). This evidence concerns the gene DNER and glioblastoma.